Gyre Therapeutics, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Gyre Therapeutics, Inc. (GYRE) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $142.49 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $142.49M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $43.09M; Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed $136.99M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $59.55M; Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed $142.28M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $137.41M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2026-06-30 | $142.49M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $43.09M 10-Q · filed 2026-08-07 | $136.99M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $59.55M 10-Q · filed 2026-08-07 | $142.28M 10-K · filed 2026-03-13 |
| 2025-09-30 | $137.41M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $59.61M 10-Q · filed 2026-08-07 | $129.44M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $40.67M 10-Q · filed 2026-08-07 | $104.30M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $35.79M 10-Q · filed 2026-08-07 | $98.40M 10-K · filed 2025-03-17 |
| 2024-09-30 | $98.47M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $93.35M 10-Q · filed 2025-11-07 | |
| 2024-03-31 | $88.77M 10-Q · filed 2025-11-07 | |
| 2023-12-31 | $13.95M 10-K · filed 2026-03-13 | |
| 2023-09-30 | $85.32M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $77.47M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $77.33M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $72.22M 10-K · filed 2025-03-17 | |
| 2021-12-31 | $59.47M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |